Statement: To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.
Primary_evidence: Inclusion Criteria:   Histologically or cytologically confirmed breast cancer   Metastatic disease   Measurable disease, defined as >=1 unidimensionally measurable lesion, including >= 1 of the following:   Lesion >= 10 mm on CT scan (5 mm sections)   Lesion >= 20 mm on CT scan or MRI (10 mm sections)   Bone disease that is >= 10 mm on MRI   Lytic bone lesions that are >= 10 mm on CT scan (with 5 mm sections) OR >= 20 mm on plain film or CT scan (with 10 mm sections)   Lesion >= 10 mm on physical exam   Patients must have received >= 1 prior aromatase inhibitor in either the adjuvant or metastatic setting and must have had either disease recurrence or disease progression on a prior aromatase inhibitor therapy   No brain metastases diagnosed within the past 6 months OR previously untreated brain metastases   Estrogen receptor-positive and/or progesterone receptor-positive, defined as > 1% staining by immunohistochemistry or > 10 fmol/mg of protein by radio-ligand dextran-coated steroid binding assay   Postmenopausal, as defined by 1 of the following:   Prior bilateral oophorectomy   No menses for >= 12 months in patients with an intact uterus   Follicle-stimulating hormone (FSH) in postmenopausal range in patients < 60 years of age who have had a prior hysterectomy or have been amenorrheic for >= 3 months   Age >= 60 years   Pre- or perimenopausal patients receiving monthly injections of goserelin at a dose of 3.6 mg are eligible   ECOG 0-2   More than 3 months   Absolute neutrophil count >= 1,500/mm3 Platelet count >= 100,000/mm3 No bleeding diathesis   Bilirubin =< 1.5 times upper limit of normal (ULN AST and ALT =< 2.5 times ULN   Systolic blood pressure (BP) < 150 mm Hg and diastolic BP < 100 mm Hg on at least one reading prior to study entry No uncontrolled hypertension   None of the following within the past 6 months:   Symptomatic congestive heart failure   Unstable angina pectoris   Myocardial infarction   Cardiac arrhythmia with hemodynamic compromise   Not pregnant or nursing   Able to swallow oral medication   No known HIV positivity   No ongoing or active infection   No psychiatric illness or social situation that would preclude study compliance   No other active invasive malignancy within the past 5 years except nonmelanoma skin cancer or treated carcinoma in situ of the cervix   No other uncontrolled illness   More than 4 weeks since prior chemotherapy   No more than 2 prior chemotherapy regimens for metastatic disease   At least 8 weeks since prior anastrozole therapy   Concurrent steroids allowed if dose is stable   More than 4 weeks since prior radiotherapy   More than 4 weeks since prior major surgery   Recovered from prior therapy   No prior sorafenib   No concurrent therapeutic anticoagulation   Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided PT and PTT are =< 1.5 times ULN   No concurrent agents that may interact with sorafenib, including any of the following:   Hypericum perforatum (St. John's wort)   Rifampin   P450 CYP3A4 enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or phenobarbital)   No other concurrent investigational agents Exclusion Criteria:   estrogen receptor status unknown   history of myocardial infarction within 6 months   performance status 3   performance status 4   premenopausal   progesterone receptor status unknown HIV positive